Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Topical Delgocitinib for Facial Vitiligo
Official title: Open-label Proof-of-concept Trial of Topical Delgocitinib in Patients With Facial Vitiligo
Status: Closed to new participants
Description:
This study is looking at a skin condition called vitiligo. Vitiligo is a skin condition where patches of the skin lose their natural color and become white. This study focuses specifically on vitiligo that affects the face. The treatment being tested is a cream called Anzupgo, which contains an active ingredient named delgocitinib. This cream is applied directly to the skin in the areas affected by vitiligo.The purpose of this study is to find out whether delgocitinib cream could be a helpful treatment for people who have non-segmental vitiligo on their face. During the study, participants will apply the cream to their facial vitiligo patches twice daily for a period of 24 weeks. The study will measure changes in the amount and appearance of the white patches on the face and other parts of the body after 4 weeks, 12 weeks, and 24 weeks of treatment.Throughout the study, doctors will check how well the treatment works by examining the size and severity of the vitiligo patches. They will also ask participants questions about how vitiligo affects their quality of life. The study will monitor any unwanted effects that might occur during treatment and at a follow-up visit 12 weeks after completion of the treatment period. Participants will have skin tape strips taken at the beginning of the study and during treatment to help researchers understand how the cream works on the skin.
Phase: Phase 2.
What is being studied: drug — Delgocitinib cream.
Who can take part: ages 18 Years, 12 participants planned.
Enrollment status: Closed to enrollment. The study started 08 April 2026 and is expected to finish 01 January 2028.
Source: ClinicalTrials.gov, NCT07820098 (https://clinicaltrials.gov/study/NCT07820098).
Start date: April 08, 2026
Completion date: January 01, 2028
Organizer: Lone Skov
Link: https://clinicaltrials.gov/study/NCT07820098
The registry does not list a contact for this study. Use the link above to reach the study record on ClinicalTrials.gov.
Clinical Trial Alerts
Sign up and be the first to know about updates on this trial.
FAQOther Questions
- What are the best predictors for therapy response in vitiligo?
A fair question. Also a slightly annoying one, because dermatology loves nuance and patients usually want something more like a weather forecast. Still, a few factors do show up...
- What causes vitiligo?
The exact cause is a complex puzzle, but we know the foundation: It is pre-wired in your genes. Think of your genetics as a loaded spring, just waiting for a specific "trigger" ...
- Do Antioxidant Supplements Help Vitiligo?
Do Antioxidant Supplements Help Vitiligo? Short answer Maybe a little. But probably not in the way most people hope. Antioxidant supplements may offer modest support, especially...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.